CUTIA-B News

CICC: Reaffirmed the "outperform" rating for Sea Ltd (02487), with the target price raised to HK$15.2.

Zhitong FinanceSep 2 14:44

Cordi-B (02487.HK): Skincare growth exceeded expectations, accounting for nearly half, and the progress of anesthetic cream exceeded expectations, and the market progressed the fastest commercialization & pipeline progress on a dual track

Aug 30 00:00

CICC: Maintains outperform rating for KeDuoB(B02487), target price lowered to HKD 11.

Zhitong FinanceAug 12 09:48

Cordi-B (02487.HK): The online listing application for table hemp tubes was accepted, and the repurchase showed the company's confidence

Aug 12 07:31

Fangzheng Securities: Liding Double Lidocaine Ointment's listing application has been accepted. Maintain a 'recommended' rating for Kodis-B (02487).

Zhitong FinanceAug 2 17:32

Cordi-B (02487.HK): The progress of acceptance of the marketing application for lidine biscaine anesthetic cream exceeded market expectations

Aug 2 07:46

Cordi-B (02487.HK): The listing application for lidine dual caine anesthetic cream was accepted, showing confidence to repurchase shares

Aug 1 07:41

Cordi-B (02487.HK): The hair and skin care product line started quickly and progressed smoothly in the research pipeline

Apr 2 17:02

Cordi-B (02487.HK) Hong Kong Stock Company Information Update Report: 2023 Revenue Exceeds Expectations and the R&D Pipeline Is Expected to Be Implemented to Contribute to Growth

Mar 30 00:00

Kodi B (02487.HK) commercialized as an innovative sail paddle and became a leading pan-dermatology platform enterprise

Mar 29 15:46

CITIC Lyon: Maintaining Kodi Group's (02487) “Buy” Rating Target Price Reduction 77% to HK$8.8

Zhitong FinanceMar 11 13:41

Cordi-B (2487.HK): Deepening R&D and Consumption Barriers to Build a Leading Integrated Dermatology Platform

Mar 6 00:00

Cordi-B (02487.HK): Forecasts revenue of about 138 million yuan in 23, and commercialization progress exceeded expectations

Mar 4 15:26

Cordi-B (02487.HK) Company Review Report: Continued Explosion of Commercialization Drives Revenue Exceeding Expectations, Heavy Pipeline to be Launched in 25 Years

Feb 29 00:00

Kodi B (02487.HK): Strong commercialization helps the off-season not fade & double 11 promotion continues to increase, and deep reserves on the R&D side are expected to be poised to go

Nov 9, 2023 00:00

Kodi B (02487.HK) First Coverage Report: R&D Drives Commercialization Orients Pan-Dermatology Market Upstart

中信證券Sep 6, 2023 18:32

Cordy-B (02487.HK): Commercialization starts smoothly and clinical product development is progressing steadily

中金公司Aug 31, 2023 00:00

Kodi (2487.HK): Smooth commercialization process boosts revenue growth, September entry is expected to further increase liquidity

信達證券Aug 30, 2023 00:00

Cordy-B (02487.HK) focuses on the needs of pan-dermatology to create a diverse product portfolio

中金公司Aug 19, 2023 00:00

CMB International: First “buy” CMB Group (02487) with a target price of HK$33.21

Zhitong FinanceJul 25, 2023 10:25